27th week of 2015 patent applcation highlights part 9 |
Patent application number | Title | Published |
20150182602 | PHARMACEUTICAL FORMULATIONS COMPRISING PARAOXONASE - The present invention provides a pharmaceutical formulation comprising paraoxonase (PON), a purification and stabilization method of PON, and an agent for prophylactic and/or therapeutic treatment of a disease resulting from ischemia reperfusion and/or cerebral infarction containing PON as an active ingredient. | 2015-07-02 |
20150182603 | METHOD AND APPARATUS FOR PREPARING SINGLE DONOR THROMBIN SERUM - A method for preparing thrombin serum, the method comprising obtaining blood fluid sample, contacting a first aliquot of the blood fluid with a procoagulant agent to form prothrombinase enzyme complex bound to the surface of the procoagulant agent so as to obtain an activated procoagulant agent that may be stored. The activated procoagulant agent may then be contacted with a second aliquot of the blood fluid containing prothrombin so as to obtain thrombin serum, which may be extracted and contacted with fibrinogen to obtain fibrin. | 2015-07-02 |
20150182604 | COMPOSITIONS COMPRISING HETEROGENEOUS POPULATIONS OF RECOMBINANT HUMAN CLOTTING FACTOR XA PROTEINS - Compositions are provided comprising recombinant variants of the human clotting Factor Xa. Such compositions include a wide variety of isoforms and post-translational modifications of FXa and are useful for treating subjects in need of hemostasis. | 2015-07-02 |
20150182605 | Ultra-Low Dose Lysostaphin for Treating MRSA - The present invention is directed to compositions and methods for treating diseases and disorders of patients and, in particular, compositions and methods for treating | 2015-07-02 |
20150182606 | Multimodal Antimicrobial Therapy - The present invention is directed to compositions and methods for preventing and/or treating diseases and disorders of patients caused by non-Staphylococcal microorganisms. In particular, compositions and methods contain lysostaphin, altered forms of lysostaphin as compared to wild-type, and synergistic combinations of lysostaphin plus additional conventional treatments such as other enzyme, antibiotic and/or antibody treatment. The invention is also directed to detecting and identifying altered forms of lysostaphin that possess increased efficacy against infections as compared to wild-type lysostaphin, and forms that generate a minimal or no immune response in a patient. The invention is also directed to method of manufacturing lysostaphin and altered forms of lysostaphin, and compositions that direct the lysostaphin to the site of the infection such as aerosolized nanoparticles. | 2015-07-02 |
20150182607 | Use of Proteases for Gluten Intolerance - The present technology relates to an enzyme composition. The enzyme composition may be used to treat gluten intolerant subjects, including suffering from non-Celiac gluten intolerance and/or non-Celiac gluten sensitivity. The enzyme composition may also be used to reduce gluten exposure in certain individuals. For example, the enzyme composition may also be used as a prophylactic to reduce exposure to gluten oligopeptides. | 2015-07-02 |
20150182608 | METHODS AND COMPOSITIONS FOR ENHANCING AN IMMUNE RESPONSE, BLOCKING MONOCYTE MIGRATION, AMPLIFYING VACCINE IMMUNITY AND INHIBITING TUMOR GROWTH AND METASTASIS - Provided are methods of enhancing an immune response and methods for reducing the recruitment of monocytes to a lymph node by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an antigen. The invention also provides relate methods for amplifying vaccine immunity by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an vaccine. The invention also provides related methods of inhibiting tumor growth and metastasis by administering to an individual with cancer an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an anti-tumor preparation. In addition, related compositions comprising an ARB or a compound of Formula (I) and an antigen, vaccine, or anti-tumor preparation are provided. | 2015-07-02 |
20150182609 | VACCINE FOR THE PREVENTION OF BREAST CANCER RELAPSE - The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods. | 2015-07-02 |
20150182610 | LIVE, ORAL VACCINE FOR PROTECTION AGAINST SHIGELLA DYSENTERIAE SEROTYPE 1 - The invention relates to | 2015-07-02 |
20150182611 | VACCINE FOR PROTECTION AGAINST SHIGELLA SONNEI DISEASE - Compositions and methods for protecting a susceptible host against an infection of | 2015-07-02 |
20150182612 | COMPOSITIONS AND METHODS FOR TREATING AN ACTIVE MYCOBACTERIUM TUBERCULOSIS INFECTION - The present disclosure relates to methods and compositions for treating a active tuberculosis infection and methods and compositions for improving the efficacy of chemotherapy regimens against active tuberculosis infection. The present disclosure relates to methods of treating an active | 2015-07-02 |
20150182613 | Meningococcal And Pneumococcal Conjugate Vaccine And Method Of Using Same - This disclosure relates to vaccine formulations comprising an immunogenic composition for inducing antibodies to both | 2015-07-02 |
20150182614 | Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology - The present invention relates to a life attenuated | 2015-07-02 |
20150182615 | Anti-bacterial Vaccine Compositions - Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines. | 2015-07-02 |
20150182616 | CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 2015-07-02 |
20150182617 | GLYCOPROTEINS FOR PSEUDOTYPING LENTIVECTORS - The invention relates to compositions and methods based on the use of viral G proteins to pseudotype vectors. The viral G proteins can be expressed by expression vectors and can be used to pseudotype lentiviral vectors. The viral G proteins can be included in a combination of compounds for sequential administration to a mammalian host. | 2015-07-02 |
20150182618 | Peptide Sequences and Compositions - Provided is a polypeptide having no more than 100 amino acids, which polypeptide comprises one or more sequences having at least 60% homology with any of SEQ ID 1-4, or comprises two or more epitopes having 7 amino acids or more, each epitope having at least 60% homology with a sub-sequence of any of SEQ ID 1-4 that has the same length as the epitope: | 2015-07-02 |
20150182619 | METHODS OF VACCINE ADMINISTRATION - This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein. | 2015-07-02 |
20150182620 | Polypeptides for use in the Prophylactic Treatment of Allergic Asthma - The present invention relates to a polypeptide derived from a mite allergen (Der p 2) useful for the prophylactic treatment of allergic asthma. | 2015-07-02 |
20150182621 | COMPOSITIONS AND METHODS FOR ENHANCING ANTIGEN-SPECIFIC IMMUNE RESPONSES - Methods for treating or preventing recurrence of hyper proliferating diseases, e.g., cancer and persistent viral infections, are described. A method may comprise priming a mammal by administering to the mammal an effective amount of a nucleic acid composition encoding an antigen or a biologically active homolog thereof and boosting the mammal by administering to the mammal an effective amount of an oncolytic virus comprising a nucleic acid encoding the antigen or the biologically active homolog thereof. | 2015-07-02 |
20150182622 | TREATMENT AND PREVENTION OF RETINAL INJURY AND SCARRING - The present invention relates to a method for the prevention of scar formation and vision loss due to laser injuries caused by exposure to laser radiation. The method involves the administration to a subject exposed to laser radiation of an effective amount of a pharmaceutical composition containing an inhibitor of c-Met activity, such as an antibody to c-Met. | 2015-07-02 |
20150182623 | Compositions Comprising an Anti-PDGF Aptamer and a VEGF Antagonist - The present invention is directed to compositions comprising an anti-PDGF aptamer and a VEGF antagonist. In certain embodiments, the compositions of the invention are useful for treating or preventing an ophthalmological disease. | 2015-07-02 |
20150182624 | USE OF NANODIAMONDS FOR GENERATING FREE RADICALS FOR THERAPEUTIC PURPOSES UNDER RADIATION - The present invention relates to the use of nanodiamonds as drugs generating free radicals, in particular for treating tumours. The invention is based on generating free radicals on the surface of the nanodiamonds when they are exposed to radiation, for example ionising radiation. In order to increase the effectiveness of the nanodiamonds, the nanodiamonds can be complexed with a radiosensitising agent, such as a chemical molecule or an interfering RNA targeting a repairing gene. | 2015-07-02 |
20150182625 | WATER-SOLUBLE LIPOPHILIC NATURAL COMPOUND FORMULATIONS - Methods and formulations for increasing the water solubility and/or bioavailability of a lipophilic natural compounds is disclosed. The formulations may be employed to make liquid filled capsules or clear and stable beverages containing therapeutic amounts of the active ingredients, for example. | 2015-07-02 |
20150182626 | Stable Aqueous Formulations of Adalimumab - The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same. | 2015-07-02 |
20150182627 | LIPOSOME INCLUDING ACTIVE INGREDIENT AND IMAGING AGENT AND USE THEREOF - A stimulus-sensitive liposome with a lipid bilayer comprising a first imaging agent, and an active ingredient and second imaging agent in an interior space defined by the lipid bilayer; a composition including the liposome; and a method of monitoring delivery and release of the active ingredient to a target site of an individual by using the liposome. | 2015-07-02 |
20150182628 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2015-07-02 |
20150182629 | STABLE COMPOSITIONS OF FESOTERODINE - Stable pharmaceutical compositions of fesoterodine or its pharmaceutically acceptable salt thereof and process for preparing the same. In a first embodiment, a stable pharmaceutical composition is provided comprising fesoterodine fumarate, glyceryl behenate and a stabilizer. The stable pharmaceutical tablet composition may further comprise i) fesoterodine fumarate in an 5 amount of 1% to 5% by weight, ii) glyceryl behenate in an amount of 1% to 8% by weight, iii) pregelatinized starch in an amount of 30% to 50% by weight and iv) a stabilizer in an amount of 0.1% to 10% by weight based on total weight of the composition. | 2015-07-02 |
20150182630 | HYDROGEL COMPOSITION FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - The present patent application is related to a hydrogel composition which is essentially free of active drugs for the manufacture of a product for the treatment of dermatological disorders, especially perioral dermatitis, acne or seborrheic dermatitis. | 2015-07-02 |
20150182631 | SYSTEM FOR DELIVERING LECTIN-BASED ACTIVE INGREDIENTS - The invention relates to the use of fungal sporocarp lectin or of a variant thereof for the delivery of an active agent to a biological target. | 2015-07-02 |
20150182632 | ANTI-INTERLEUKIN-1 (IL-1) ANTIBODY USED AS A TARGETING AGENT TO TREAT ARTHRITIS AND OTHER DISEASES - This invention describes the use of anti-IL-1 antibody as a targeting agent attached to liposomes incorporating anti-inflammatory drugs to treat arthritis and other inflammatory diseases. A variety of steroidal and non-steroidal drugs and disease modifying drugs and other anti-inflammatory compounds may be incorporated into the anti-IL-1 antibody coated liposomes. The anti-IL-1 antibody coated drug liposomes will accumulate within the inflamed site where the drug is released for maximum therapeutic effect. Other nanosized drug delivery vehicles such as dendrimers, micelles, nanocapsules and nanoparticles may be similarly coated with anti-IL-1 antibody and used to deliver the drug to the site of inflammation. Also in lieu of the anti-IL-1 antibody other IL-1 binding agents such as anti-IL-1 aptamers and anti-IL-1 binding peptides may be used to coat various nanosized drug delivery vehicles in order to deliver the drug to the site of inflammation. | 2015-07-02 |
20150182633 | Immunoconjugates with an Intracellularly-Cleavable Linkage - The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates. | 2015-07-02 |
20150182634 | Molecular Design and Chemical Synthesis of Pharmaceutical-Ligands and Pharmaceutical-Pharmaceutical Analogs with Multiple Mechanisms of Action - Multi-phase and single-phase chemical reaction schemes have been developed for the synthesis of pharmaceutical-ligand analogs, pharmaceutical-pharmaceutical analogs, and similar molecular-molecular analogs that possess multiple mechanisms of action. The multi-phase organic chemical reaction schemes include relatively mild reaction conditions, high end product yields, and comparatively rapid completion of chemical reactions, which are all of particular utility for the synthesis of preparations including covalent pharmaceutical-receptor ligand or pharmaceutical-immunoglobulin analogs. Examples of pharmaceutical-ligand preparations that can be synthesized utilizing the multi-step chemical reaction schemes include covalent chemotherapeutic-ligand agents that possess selective targeted delivery properties and a capacity to exert additive and synergistic levels of cytotoxic anti-neoplastic potency. Pharmaceutical-pharmaceutical analogs, including chemotherapeutic-chemotherapeutic analogs that are capable of exerting multiple mechanisms of action, can be synthesized using either of the described multi-phase or single-phase organic chemistry reaction schemes. Each of these representative examples has utility against a spectrum of disease states including, for example, neoplastic conditions such as mammary adenocarcinoma/carcinoma, ovarian carcinoma, prostatic carcinoma, intestinal carcinoma, melanoma, leukemia, myeloma, and lymphoma. | 2015-07-02 |
20150182635 | PROCESS FOR PREPARING PURIFIED DRUG CONJUGATES - The invention provides a process for preparing a cell-binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purification step. | 2015-07-02 |
20150182636 | GENETICALLY MODIFIED HUMAN UMBILICAL CORD PERIVASCULAR CELLS FOR PROPHYLAXIS AGAINST OR TREATMENT OF BIOLOGICAL OR CHEMICAL AGENTS - The invention provides methods of preventing or treating diseases or disorders caused by biological agents or chemical agents in a subject (e.g., a mammal, such as a human) by administering genetically modified human umbilical cord perivascular cells. | 2015-07-02 |
20150182637 | WIDESPREAD GENE DELIVERY OF GENE THERAPY VECTORS - The present invention relates to improved compositions and methods for delivering and expressing therapeutic genes in mammals. More particularly, the invention stems from the unexpected discovery that a remarkable, massive and widespread therapeutic gene delivery and expression is obtained in mammals when a therapeutic gene is incorporated in a viral vector and administered both into the CSF and into the blood of the mammal. Such a combined administration leads to a surprising and substantial therapeutic benefit in the mammal as compared to administration in one single site, and further enables the use of reduced doses of the virus. The invention may be used in any mammal, including human subjects, and is particularly suited to treat multi-systemic diseases, such as motor neuron or lysosomal disorders, where widespread expression of a therapeutic gene is desirable. | 2015-07-02 |
20150182638 | VIRUS-MEDIATED DELIVERY OF BEVACIZUMAB FOR THERAPEUTIC APPLICATIONS - The invention provides a method of inhibiting ocular neovascularization in a mammal by administering a composition comprising a bevacizumab-encoding adeno-associated virus (AAV) vector directly to the eye of the mammal. | 2015-07-02 |
20150182639 | COMPOSITION AND METHOD FOR MEDICAL IMAGING OR BODY CAVITIES - The present invention relates to an image enhancing composition for the enhancement of contrast in a body cavity, wherein the viscosity of the composition is between 2000 and 4000 mPa·sec. It also relates to a method for enhancing contrast of an image of a body cavity, which method comprises introducing one single small amounts of an image enhancing composition into the body cavity. In another aspect, the present invention provides a high contrast image of a body cavity obtained by the method of the invention, in particular a 3-dimensional high contrast image. | 2015-07-02 |
20150182640 | PH SENSITIVE FLUORESCENT POLYDIACETYLENE LIPOSOME AND DELIVERY VEHICLE COMPRISING SAME - The present invention relates to a drug delivery vehicle comprising a polydiacetylene liposome, wherein lipid bilayer is formed by a mixture of 10,12-pentacosadiynoic acid (PCDA), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and N-palmitoyl homocysteine (PHC), and a drug to be delivered is encapsulated in an isolated inner space of a polydiacetylene liposome. The PDA liposome drug delivery vehicle of the present invention comprises a lipid layer formed by mixing different phospholipids, excluding polydiacetylene, so as to be stable, and thus any leakage problems of an encapsulated drug are eliminated. In addition, since the liposome is sensitive to a pH, the shape and size thereof can be readily changed through the formation of a liposome-liposome conjugate by the improved sensitivity of the drug delivery vehicle under a specific acidic requirement, thereby enabling selective drug release, and thus can be applied as a drug delivery vehicle for various target materials. Additionally, the release of a drug can be controlled by controlling a pH requirement of the surroundings, and a drug release process can be monitored in real time through the fluorescence expressed by the stimulation to the surroundings. | 2015-07-02 |
20150182641 | NANOPARTICULATE CONTRAST AGENT - Provided is a nanoparticulate composite with two layers. One of the layers comprises one or more metals, which are a paramagnetic metal, a ferromagnetic metal, or a superparamagnetic metal. This layer also contains one or more suitable dopants. The other layer comprises one or more metals of gadolinium, manganese (II), and iron (III), in the form of an oxide or a fluoride. This layer may contain one or more lanthanide dopants. The nanoparticulate composite may be used as a contrast agent, in particular in magnetic resonance imaging. | 2015-07-02 |
20150182642 | GRAPHENE-BASED CONTRAST AGENTS FOR PHOTOACOUSTIC AND THERMOACOUSTIC TOMOGRAPHY AND METHOD OF USE - The present invention provides a composition for use with photoacoustic or thermoacoustic imaging, comprising a sufficient amount of the graphene-like nanoparticles or graphitic nano- or microparticles and one or more physiologically acceptable carriers or excipients. The present invention also provides methods of using the graphene-like nanoparticles or graphitic nano- or microparticles as PAT/TAT contrast agents. | 2015-07-02 |
20150182643 | Novel Substrate Based PET Imaging Agents - The present application is directed to radiolabeled imaging agents comprising a radiolabel, and a substrate, pharmaceutical compositions comprising radiolabeled imaging agents, and methods of using the radiolabeled imaging agents. The present application is further directed to methods of preparing the radiolabeled imaging agent. Such imaging agents can used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT). | 2015-07-02 |
20150182644 | COMPOUNDS AND METHODS FOR THE DETECTION OF TRPV-6 CANCERS AND DRUG DELIVERY - Compounds containing TRPV6-binding peptides and their use in the detection and diagnosis of cancer are described. Also described are methods for detecting and staging cancer that use the compounds of the invention. Compounds containing TRPV6-binding peptides are useful for the delivery of diagnostic and therapeutic agents to cells or tumors that express TRPV6. | 2015-07-02 |
20150182645 | Prophylactic Bactericidal Medical Device - A medical implant system is described for inhibiting infection associated with a joint prosthesis implant. An inventive system includes an implant body made of a biocompatible material which has a metal component disposed on an external surface of the implant body. A current is allowed to flow to the metal component, stimulating release of metal ions toxic to microbes, such as bacteria, protozoa, fungi, and viruses. One detailed system is completely surgically implantable in the patient such that no part of the system is external to the patient while the system is in use. In addition, externally controlled devices are provided which allow for modulation of implanted components. | 2015-07-02 |
20150182646 | INACTIVATION OF GRAM-POSITIVE BACTERIA - A method for inactivating medically important Gram-positive bacteria including Methicillin-resistant | 2015-07-02 |
20150182647 | Touchscreen Sanitizing System - A sanitizing system for use with monitors, particularly including touchscreen monitors, includes an ultraviolet light source positioned about a periphery of the monitor and configured to transmit light toward the monitor. A sensor detects the presence of an object such as a human finger in the close vicinity or in contact with the monitor in order to stop the operation of the lights. | 2015-07-02 |
20150182648 | COMBINATION ELECTRONIC DEVICE DOCK AND DISSINFECTOR - Disclosed is a disinfecting station for at least one portable electronic device. An enclosure is adapted to receive the at least one portable electronic device therein through an openable side that includes a selectively closable door. Each electronic device is exposed to a disinfecting wavelength of light, such as UV light, to disinfect the surface of the device. The enclosure can include supports that minimally contact each device so that the device will be substantially exposed to the UV light. A control circuit can monitor the exposure time and level, and is programmable to activate the UV light based on pre-set criteria. The enclosures may be stacked and provide power and network connectivity to each device while docked therein. | 2015-07-02 |
20150182649 | STERILISATION AND DECONTAMINATION DEVICE - A sterilisation, sanitisation and/or decontamination device | 2015-07-02 |
20150182650 | PORTABLE DECONTAMINATION UNIT - An apparatus for decontaminating a region within an enclosure. The apparatus comprises a conduit having a passageway therethrough that defines a path for a carrier gas. A plurality of tube sections, each of the tube sections having an opening extending therethrough, is selectively movable into and out of a gap in the conduit. A heating element is disposed in one of the tube sections and is operable to heat the carrier gas flowing therethrough. A destroyer is disposed in another of the tube sections and is operable to destroy sterilant in the carrier gas. A controller controls movement of the tube sections into and out of the gap. | 2015-07-02 |
20150182651 | DECONTAMINATION PROCESS DEVICE AND DECONTAMINATION PROCESS METHOD - A decontamination process device includes a chamber that contains a decontamination target, a heating device that generates decontamination vapor, an air sending part that sends the decontamination vapor into the chamber, a ventilation system that ventilates the chamber, a controller that controls operations of the decontamination process device. The controller performs a supply process that supplies the decontamination vapor into the chamber and an elimination process that eliminates a decontamination component after the supply process. The ventilation system adjusts an ventilation amount and the controller is set to repeat the supply processes at multiple times, and to perform a dry process between the repeated supply processes and to maintain the chamber at a positive pressure during the dry process. | 2015-07-02 |
20150182652 | SELF-POWERED PIEZOELECTRIC STRUCTURE AND METHOD OF MANUFACTURING THE SAME - According to an illustrative embodiment of the present invention, a self-powered piezoelectric structure is provided which includes a base material that can be bent by an externally applied force, and a catalyst layer formed on the base material, wherein the catalyst layer is formed by using a mixture of a catalytic material, which can be activated when the energy is applied thereto from an outside, and a piezoelectric material. | 2015-07-02 |
20150182653 | AUTOMATED STERILIZATION PROCESS INTEGRATED WITH A BLOW FILL SEAL MACHINE - A process and system for sterilization of a product pathway of a blow-fill-seal machine. The process comprises steps of: (1) isolating a holding tank from the product pathway; (2) supplying a sterilizing agent to the product pathway of the BFS machine when the holding tank is isolated; (3) stopping the supply of sterilizing agent to the product pathway when a threshold is reached; and (4) supplying filtered compressed air to the product pathway when the supply of sterilizing agent is stopped. The process is preferably executed automatically without human intervention once initiated. Also described is a system for carrying out the process including a processor, valves and temperature and/or pressure sensors which provide information to the processor to determine when to open and close the valves to supply sterilizing agent and/or compressed air to the product pathway or holding tank. | 2015-07-02 |
20150182654 | AIR PURIFICATION SYSTEM - An air purification system includes an internally hollow cylindrical casing made of a non-conducting material; an inner electrode arranged on an inner surface of the supporting member; an outer electrode arranged on an outer surface of the supporting member; a photocatalyst filter arranged on an outer surface of the outer electrode for purifying air inside a plasma generation zone; and a power source for supplying power of opposite polarities to each of the inner electrode and the outer electrode so as to generate plasma. The photocatalyst filter includes a filter element, and the filter element includes a porous titanium foil having a non-periodic spongy structure impregnated with anatase titanium dioxide particles as a photocatalyst. | 2015-07-02 |
20150182655 | BINARY ODOR CONTROL SYSTEM FOR ABSORBENT ARTICLES - Cellulosic pulp structures integrating unreacted quantities of an inorganic peroxide and a destabilizing acid, as binary components of an odor control system, absorbent articles incorporating such structures, and various methods of forming the same, are disclosed herein. The components are adapted to react in the presence of an aqueous fluid to produce hydrogen peroxide, thereby providing an antimicrobial and odor mitigating effect. | 2015-07-02 |
20150182656 | Perfume Compositions - Perfume compositions comprise between 10% and 30% in total weight of perfume ingredients selected from two groups, Group A, Group B, with the provisos that over 5% but less than 15% of the perfume composition must comprise Group A ingredients, and for compositions comprising less than 10% of Group A ingredients in the aggregate percentage of Group B ingredients present must be at least equal to the expression (2*/10−A %) where A % is the total percentage of Group A ingredients in the composition. | 2015-07-02 |
20150182657 | ACTIVE POLYMER LAYER MADE OF CHITIN DERIVATIVES, ESPECIALLY FOR A DRESSING, AND ITS USE - The invention refers to an active polymer layer ( | 2015-07-02 |
20150182658 | EMBOLIZATION - A particle includes a ferromagnetic material, a radiopaque material, and/or an MRI-visible material. | 2015-07-02 |
20150182659 | METHODS AND KITS FOR REVERSIBLE ADHESION OF IMPLANTS TO AN EYE SCLERA - Methods and kits are provided for reversibly affixing an implant to a sclera of an eye of a subject. The methods and kits are based on applying a composition comprising at least one fibrin-based tissue adhesive to at least one of said implant and said sclera, thereby affixing said implant to the sclera, and applying a composition comprising at least one plasminogen activator to at least one of said implant and said sclera following a desired time-period, thereby detaching said implant from said sclera, and removing said implant from said eye. | 2015-07-02 |
20150182660 | DENSE HYDROGELS - There is provided a method for preparing a dense hydrogel comprising providing an at least partially gelled hydrogel, placing the at least a partially gelled hydrogel in fluid communication with an end of a capillary, and driving the at least partially gelled hydrogel into the capillary to form a dense hydrogel. There is also provided a system for preparing the dense hydrogel comprising a capillary having a bore; and a driver in communication with an end of the capillary for driving an at least partially gelled hydrogel into the bore of the capillary to form a dense hydrogel. | 2015-07-02 |
20150182661 | PLACENTAL TISSUE GRAFTS AND IMPROVED METHODS OF PREPARING AND USING THE SAME - A method for preparing placenta membrane tissue grafts for medical use, includes obtaining a placenta from a subject, cleaning the placenta, separating the chorion tissue from the amniotic membrane, mounting a selected layer of either the chorion tissue or the amniotic membrane onto a drying fixture, dehydrating the selected layer on the drying fixture, and cutting the selected layer into a plurality of tissue grafts. Preferably, the drying fixture includes grooves or raised edges that define the outer contours of each desired tissue graft, after they are cut, and further includes raised or indented logos that emboss the middle area of the tissue grafts during dehydration and that enables an end user to distinguish the top from the bottom side of the graft. The grafts are comprised of single layers of amnion or chorion, multiple layers of amnion or chorion, or multiple layers of a combination of amnion and chorion. | 2015-07-02 |
20150182662 | Compositions and Methods for Treatment of Cardiovascular Disorders - ECM based compositions including amniotic membrane and methods for employing same to treat cardiovascular disorders. | 2015-07-02 |
20150182663 | Extracellular Matrix Based Gastroesophageal Junction Reinforcement Device - Provided are medical devices for implantation in patients having suffered the loss of or damage to at least part of their esophagus. The medical device connects the esophagus or remaining part thereof with the stomach to form a gastro-esophageal junction that promotes healing and encourages new host tissue growth while distributing the load and decreasing tension at the anastomotic site. The medical device comprises extracellular matrix shaped into a conformation that more closely approximates the geometry of the native gastro-esophageal junction than does direct attachment of the stomach to the shortened esophagus. Molds useful in manufacturing the medical device and methods of use of the device are also described herein. | 2015-07-02 |
20150182664 | Tissue Products Derived from Animals Lacking any Expression of Functional Alpha 1, 3 Galactosyltransferase - The present invention provides tissues derived from animals, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha-1,3-GT). Such tissues can be used in the field of xenotransplantation, such as orthopedic reconstruction and repair, skin repair and internal tissue repair or as medical devices. | 2015-07-02 |
20150182665 | METHODS FOR STABILIZING A BIOPROSTHETIC TISSUE BY CHEMICAL MODIFICATION OF ANTIGENIC CARBOHYDRATES - Methods are provided herein for modifying antigenic carbohydrate epitopes within a xenographic bioprosthetic tissue by oxidation of vicinal diols to form aldehydes or acids and subsequence reductive amination of aldehydes to form stable secondary amines, or amidation or esterification of acids to form stable amides or esters. Advantageously, methods provided herein mitigate the antigenicity of the bioprosthetic tissue while leaving the overall tissue structure substantially undisturbed, and thereby enhance the durability, safety and performance of the bioprosthetic implant. | 2015-07-02 |
20150182666 | HYALURONIC ACID-CALCIUM PHOSPHATE COMPOSITE FOR GROWTH FACTOR SUPPORT AND METHOD FOR PRODUCING SAME - The present invention relates to a carrier for growth factor related to regeneration of bone tissues that is capable of arbitrarily controlling the delivery rate of growth factors related to bone regeneration and thus especially applicable to a bone void filler in the fields of the dental or orthopedic applications. | 2015-07-02 |
20150182667 | Composition with Biofilm Dispersal Agents - Embodiments of the presently-disclosed subject matter provide composites that comprise a tissue graft and a biofilm dispersal agent. The tissue graft can be bone tissue graft, a soft tissue graft, or the like. In specific embodiments the tissue graft is a polyurethane graft and in other embodiments the tissue graft is bone particles, such as demineralized bone matrix. The biofilm dispersal agent can be one or more D-amino acids. The presently-disclosed subject matter further includes methods for treating tissue of a subject that comprise administering the present composites as well as methods for manufacturing the present composites. | 2015-07-02 |
20150182668 | Electrospun PTFE Encapsulated Stent & Method of Manufacture - A stent or other prosthesis may be formed by encapsulating a scaffold or frame with a polymer coating. The polymer coating may consist of layers of electrospun polytetrafluoroethylne (PTFE). Electrospun PTFE of certain porosities may permit endothelial cell growth within the prosthesis. The stent may be applicable to stents designed for the central venous system, peripheral vascular stents, abdominal aortic aneurism stents, bronchial stents, esophageal stents, biliary stents, or any other stent. | 2015-07-02 |
20150182669 | PARTICLE DELIVERY - A method for delivering particles to a target location of a subject includes slidably disposing a polymeric carrier in a lumen of a catheter. The lumen extends in the catheter from a proximal opening to a delivery region. The method further includes inserting the delivery region of the catheter in the target location of the subject and forcing the particles through the lumen of the catheter to cause the carrier and the particles to exit the delivery region of the catheter. The particles may be cells or drug-loaded microspheres. The carrier can serve to retain the particles in the target location for a period of time. For treatment of vertebral disc degeneration, the particles can be stem cells, the carrier can be formed from collagen, and the target location can be the nucleus pulposus. | 2015-07-02 |
20150182670 | Medical Implants Including Laminates of Poly-4-Hydroxybutyrate and Copolymers Thereof - Methods to produce laminates including layers of constructs made from P4HB and copolymers thereof have been developed. These laminates may be used as medical implants, or further processed to make medical implants. The laminates are produced at a temperature equal to or greater than the softening points of the P4HB or copolymers thereof. The layers may include oriented forms of the constructs. Orientation can be preserved during lamination so that the laminate is also oriented, when the laminates are formed at temperatures less than the de-orientation temperatures of the layers. The laminate layers may include, for example, films, textiles, including woven, knitted, braided and non-woven textiles, foams, thermoforms, and fibers. The laminates preferably include one or more oriented P4HB films. | 2015-07-02 |
20150182671 | IMPLANTABLE OR INSERTABLE MRI-DETECTABLE MEDICAL DEVICE HAVING A COATING COMPRISING PARAMAGNETIC IONS AND A PROCESS FOR PREPARING IT - The present invention concerns a medical device detectable by magnetic resonance imaging (MRI), said medical device comprising an envelope polymer that is at least partly removed at the distal end of the medical device wherein said distal end is provided with a coating comprising a coating polymer modified with at least one chemical compound having one or more chemically active free functional groups to provide a surface coating covalently bonded to the free functional groups of the modified coating polymer, wherein paramagnetic ions are encompassed in the coating. | 2015-07-02 |
20150182672 | COATINGS FOR IMPLANTABLE MEDICAL DEVICES - The present application teaches a coating having a biologically compatible compound conjugated to, or blended with, a polymer, wherein the polymer includes at least one olefin-derived unit and at least one unit derived from a vinyl alcohol, an allyl alcohol, or derivatives thereof. | 2015-07-02 |
20150182673 | FUNCTIONALIZED LUBRICIOUS MEDICAL DEVICE COATINGS - In some aspects of the present invention, coatings are provided which provide lubricity as well as additional functionality. Further aspects of the invention pertain to medical devices having such coatings and methods of forming such coatings. | 2015-07-02 |
20150182674 | BIODEGRADABLE COMPOSITE WIRE FOR MEDICAL DEVICES - A bioabsorbable wire material includes manganese (Mn) and iron (Fe). One or more additional constituent materials (X) are added to control corrosion in an in vivo environment and, in particular, to prevent and/or substantially reduce the potential for pitting corrosion. For example, the (X) element in the Fe—Mn—X system may include nitrogen (N), molybdenum (Mo) or chromium (Cr), or a combination of these. This promotes controlled degradation of the wire material, such that a high percentage loss of material the overall material mass and volume may occur without fracture of the wire material into multiple wire fragments. In some embodiments, the wire material may have retained cold work for enhanced strength, such as for medical applications. In some applications, the wire material may be a fine wire suitable for use in resorbable in vivo structures such as stents. | 2015-07-02 |
20150182675 | Ascorbic Acid-Eluting Implantable Medical Devices, Systems, and Related Methods - Implantable medical devices may elute drugs that promote the growth of endothelial cells while inhibiting the growth of smooth muscle cells. In some instances, implantable medical devices may elute L-ascorbic acid, or vitamin C. In some instances, an implantable medical device configured to elute L-ascorbic acid may be a stent, although a variety of other implantable medical devices are contemplated. | 2015-07-02 |
20150182676 | SYSTEM AND METHOD FOR COLLECTING EXUDATES - A reduced pressure treatment system includes a porous pad positioned at a tissue site and a canister having a collection chamber, an inlet, and an outlet. The inlet is fluidly connected to the porous pad. A reduced pressure source is fluidly connected to the outlet of the canister to such that fluid from the tissue site may be drawn into the collection chamber. A hydrophobic filter is positioned adjacent the outlet to prevent liquid from exiting the collection chamber through the outlet. A baffle is positioned within the canister to create a tortuous path between the inlet and the outlet to prevent premature blocking of the hydrophobic filter. | 2015-07-02 |
20150182677 | WOUND DRESSING AND METHOD OF TREATMENT - Embodiments disclosed herein are directed to negative pressure treatment systems and wound dressing systems, apparatuses, and methods that may be used for the treatment of wounds. In particular, some embodiments are directed to improved wound dressings comprising an obscuring layer that may hide fluid contained therein. Some embodiments may further comprise one or more viewing windows disposed therethrough so as to enable monitoring or examination of fluids contained therein. | 2015-07-02 |
20150182678 | FUNCTIONALLY-CLOSED, STERILE BLOOD PROCESSING SOLUTION SYSTEM AND METHOD - Delivering a blood processing solution to blood in a blood bag includes coupling a first tube to a vented spike at one end and to a Y-shaped tube connector at a second end. An in-line microbiotic barrier filter is coupled to the first tube between its ends. A second tube is coupled to a transfer bag at one end and to the Y-shaped tube connector at its other end. A third tube is coupled to the output of the Y-shaped tube connector and sealed at its distal end. The blood bag includes a fourth tube that is sealed at a distal end. The third tube is welded to the fourth tube using a sterile tubing welder, wherein a functionally-closed, sterile flow path through which the blood processing solution can flow into the blood bag is maintained. | 2015-07-02 |
20150182679 | TISSUE-ENGINEERED PUMPS AND VALVES AND USES THEREOF - The present invention provides tissue-engineered pumps and valves, methods of fabricating such pumps and valves, and methods of use of such pumps and valves. | 2015-07-02 |
20150182680 | MEDICAL APPARATUS FOR EXTRACORPOREAL BLOOD TREATMENT AND METHOD FOR DETERMINING A BLOOD PARAMETER VALUE IN A MEDICAL APPARATUS THEREOF - A medical apparatus for extracorporeal blood treatment and a method for determining blood parameter value have been provided. The medical apparatus has a control unit ( | 2015-07-02 |
20150182681 | AMBULATORY LUNG ASSIST DEVICE WITH IMPLANTED BLOOD PUMP AND OXYGENATOR - The present disclosure provides a system for oxygenating blood. The system may include an implantable blood pump that may draw a supply of blood from the circulatory system of a mammalian subject, such as a human being. The blood pump may provide the supply of blood to an adaptor, where the supply of blood may be supplied to either or both of a first branch or second branch. The first branch may lead to an external blood oxygenator. The oxygenator may oxygenate the blood, and the blood may be returned to the circulatory system of the mammalian subject. The second branch may bypass the oxygenator and may connect to the circulatory system of the mammalian subject. In this regard, while the blood is supplied to the second branch, the oxygenator may be disconnected and blood may be prevented from entering the first branch. | 2015-07-02 |
20150182682 | METHOD FOR SIZED-BASED CELL SEPARATION USING SPINNING MEMBRANE FILTRATION - A method is provided for separating a suspension of cellular material comprising at least two differently-sized cell types using a spinning membrane separator. The method comprises selecting the cell type to be separated by passing through the membrane; determining a concentration of the selected cell type in the suspension; selecting an inlet flow rate for the suspension; selecting a rotational speed for the spinning membrane separator related to one or more of the concentration and relative size of the selected cell type in the suspension; rotating the spinning membrane separator at the selected rotational speed so that the selected cell type tends to migrate to regions of the shear field adjacent the porous membrane; and flowing the suspension through the spinning membrane separator. | 2015-07-02 |
20150182683 | CHAMBER FOR A BLOOD TREATMENT SYSTEM, BLOOD TUBING SYSTEM, AND BLOOD TREATMENT SYSTEM - The present invention relates to a chamber for a blood treatment system having a blood inlet and a blood outlet, a filter element for air separation which is arranged at the head side with respect to the position of the chamber in the operating state and which can be decoupled from the blood present in the chamber in the operating state by means of a further liquid, to a blood hose system and to a blood treatment system. | 2015-07-02 |
20150182684 | ISOLATING CARDIAC CIRCULATION - In a method for substantially isolating cardiac circulation from systemic circulation, flow between the coronary sinus and the right atrium is occluded. A venous collection device having a collection lumen and a support structure is located in the coronary sinus. The support structure is used to maintain patency of the coronary sinus during collection of fluid through the collection lumen. An artificial flow path is provided between the collection lumen and the one or more coronary arteries, thus isolating the cardiac circulation. According to the method, cardiac pumping for systemic circulation can be maintained during isolation of the cardiac circulation. | 2015-07-02 |
20150182685 | MEDICAL/SURGICAL IRRIGATOR THAT IS RELEASEABLY COUPLED TO AND POWERED BY A POWERED SURGICAL TOOL - An irrigator that is powered by a surgical tool capable of driving an implement. The irrigator includes a pump contained in a pump housing adapted for attachment to the tool. The irrigator includes a tip assembly connected to the pump by a flexible supply tube. Thus the tip assembly can be position against tissue against which the irrigating fluid is to be applied without having to likewise position the tool and the pump. | 2015-07-02 |
20150182686 | MEDICAL INSTRUMENT HOUSING CONTAINER - A medical instrument housing container includes a container body including a substantially rectangular base, a peripheral wall having a lower end that is contiguous to a perimeter of the base and that extends upward, and a peripheral edge member that comprises a plurality of peripheral edges, that is contiguous to an upper end of the peripheral wall, and that extends outwardly, wherein the substantially rectangular base, the peripheral wall, and the peripheral edge member are molded from resin, and the container body has an opening surrounded by the peripheral edge member; a plurality of medical instruments held in the container body; and a protection film that is adhered or heat-sealed to the peripheral edge member for covering and sealing the opening. At least a portion of the peripheral edge member is curved inwardly. The protection film covers the opening in a flexed condition. | 2015-07-02 |
20150182687 | Devices, Systems And Methods For Determining Parameters Of One Or More Phases Of An Injection Procedure - A fluid injection apparatus includes at least one pressurizing mechanism and at least a first fluid container (for example, a syringe or a bulk container) operably associated with the at least one pressurizing mechanism. The first fluid container is adapted to contain a first fluid to be injected. The fluid injection apparatus also includes a pressure modeling system adapted to predict a pressure to be generated at one or more points in the injection fluid path during planned injection procedure based upon variables associated with an injection protocol. | 2015-07-02 |
20150182688 | DEVICES AND METHODS FOR DELIVERING A BENEFICIAL AGENT TO A USER - Drug delivery reservoir cassette for a pump is provided. The cassette includes a cassette housing having a front surface, a back surface and lateral sidewalls, the cassette housing defining a transverse axis extending between the lateral sidewalls and a longitudinal axis perpendicular to the transverse axis. The cassette housing includes a cassette body region defining a fluid reservoir chamber therein, and a cassette base region having a boundary configured to be received by the pump, the boundary including a pair of opposing rails disposed on opposite sides of the longitudinal axis. The cassette base region can also include an engagement surface, alignment key, and/or support rib to align the cassette in a receiving region of the pump. A device for delivering a beneficial agent including a pump and cassette is also provided. | 2015-07-02 |
20150182689 | DEVICES AND METHODS FOR DELIVERING A BENEFICIAL AGENT TO A USER - Device for delivering a beneficial agent includes a cassette including a cassette housing with a fluid reservoir and a cassette base region. The device also includes a delivery tube. The device also includes a pump including a pump housing containing a pump assembly having a fluid drive component. The pump housing has a receiving region to receive the cassette base region. The fluid drive component is proximate the receiving region. A lock member is coupled to the pump housing and movable between an open position and a closed position. The cassette is capable of being inserted into and removed from the receiving region when the lock member is in the open position, and the cassette is secured to the pump with the cassette base region within the receiving region and the delivery tube in operative engagement with the fluid drive component when the lock member is in the closed position. | 2015-07-02 |
20150182690 | MEDICAL PARAPHERNALIA CARRIER ASSEMBLY - A medical paraphernalia carrier assembly for carrying medical paraphernalia adjacent a patient care bed includes a base assembly and a paraphernalia support assembly. A coupling assembly couples the base assembly and the paraphernalia support assembly in a manner that permits the paraphernalia support assembly to be displaceable between lateral sides of a bed when the base assembly is located intermediate the lateral sides of the bed; | 2015-07-02 |
20150182691 | AUTO-INJECTOR - Provided is a cassette unit suitable for use with an auto-injector having an electrically powered drive unit. The cassette unit comprises a cassette unit housing defining a cassette unit housing cavity and a needle projection aperture. The housing cavity may receive a syringe. Axially movable within the barrel of the syringe for forward movement into contact with the syringe plunger, there is a plunger slaving part defining a circumferential wall arranged for frictional sliding relationship with the inner wall of the barrel, a rear drive-receiving face and a front plunger-contacting face. The plunger slaving part is arranged such that when a drive load is applied to its rear drive-receiving face to bring the front plunger-contacting face into contact with the plunger the drive load is evenly transmitted. The circumferential wall is provided with slide restrictors that restrict frictional sliding movement thereof in relation to the inner wall of the barrel. | 2015-07-02 |
20150182692 | Liquid Infusion Apparatus - The present invention relates to a liquid infusion apparatus, including: a finger module provided in a main body such that the finger module can elastically move backward from a liquid delivery tube; a tube clamp, in which two clamp bodies spaced apart from each other approach each other by means of restoring force of an elastic member upon the opening of a door during infusion, so as to compress and block the liquid delivery tube; and a tube blockage detection device which detects whether the liquid delivery tube is blocked by a cause, for example, when the outlet-side portion of the liquid delivery tube, which delivers medicinal liquid pumped by a liquid pump during infusion, is bent. | 2015-07-02 |
20150182693 | SYSTEM AND METHOD FOR MODIFYING MEDICAMENT DELIVERY PARAMETERS AFTER A SITE CHANGE - Apparatuses and methods for delivery of medicaments such as insulin disclosed herein can increase the effectiveness of therapy by adjusting medicament delivery parameters to account for the loss of medicament absorption upon delivering medicament at a new insertion site. When a needle is inserted at a new site on a patient's body for delivery of medicament to that patient, a natural inflammatory response by the body to insertion of the needle causes the body to resist absorption of the delivered medicament. However, this medicament resistance decreases over time. Embodiments of the invention therefore adjust medicament delivery to deliver less medicament as time passes after an infusion set change causes medicament to be delivered at a new insertion site. | 2015-07-02 |
20150182694 | SAFETY PROCESSOR FOR WIRELESS CONTROL OF A DRUG DELIVERY DEVICE - A system and method provide for enhanced reliability and safety of programming and/or operating a medical device, such as an infusion pump, with a remote control device, such as a mobile phone (e.g., a smartphone). A safety processor acts as an intermediary device between the smartphone and medical device to review transmissions from the smartphone prior to the transmissions being delivered to the medical device. The safety processor can determine whether the smartphone is compatible with the medical device by checking the type and version of the smartphone as well as the versions of the operating software and/or firmware resident on the phone. The safety processor can also check whether the operating command entered into the smartphone is within acceptable parameters. | 2015-07-02 |
20150182695 | INTEGRATION OF INFUSION PUMP WITH REMOTE ELECTRONIC DEVICE - A system and method can provide for a remote electronic device to be used to remotely initiate delivery of a medicament bolus with a medical device, such as an insulin pump, with the medical device providing audible or tactile confirmation of the programmed bolus. The bolus amount can be calculated by or programmed or otherwise entered into the smartphone, etc., and then transmitted to the medical device. When the pump receives the transmitted bolus amount, it issues one or more indications such as audible sounds and/or vibrations in any number of desired combinations. For instance, each individual sound or vibration may correspond to an increment of the medicament. The user can therefore determine the size of the medicament bolus by the number of sounds or vibrations and can confirm or cancel delivery of the bolus. | 2015-07-02 |
20150182696 | AUTOMATICALLY DISASSOCIATING MEDICAL DEVICES FROM PATIENTS - Systems, methods, computer storage media, and user interfaces are provided for automatically disassociating medical devices from patients. An indication that a medical device is associated with a patient and is online is received. A disruption in the communication with the medical device that has not been disassociated with the patient is identified. In embodiments, the disruption indicates the medical device has lost a wireless connection, is associated with a scheduled downtime, has been powered off, or is offline. Once it is determined that a predetermined period of time has elapsed since the disruption, the medical device is automatically disassociated from the patient. In embodiments, the medical device is retroactively re-associated to the patient if it is determined the medical device should not have been automatically disassociated from the patient. | 2015-07-02 |
20150182697 | PUMP, MOTOR AND ASSEMBLY FOR BENEFICIAL AGENT DELIVERY - Device for delivering a beneficial agent to a user includes a cassette including a cassette housing with a fluid reservoir, the cassette housing having a cassette base region, and a delivery tube. The device also includes a pump having a pump housing containing a pump assembly and having a receiving region to receive the cassette base region. The pump assembly includes a fluid drive component, a display, a plurality of input buttons. The pump assembly also includes a first processor coupled to the fluid drive component and the display and configured to reduce power to the fluid drive component and the display when the pump is in an inactive state, and a second processor coupled to the first processor and the plurality of input buttons, the second processor configured to provide an activation signal to the first processor when one or more of the plurality of input buttons is deployed. | 2015-07-02 |
20150182698 | PUMP, MOTOR AND ASSEMBLY FOR BENEFICIAL AGENT DELIVERY - Device for delivering a beneficial agent to a user includes a cassette including a cassette housing with a fluid reservoir defined therein, the cassette housing having a cassette base region, and a delivery tube fluidly coupled with the fluid reservoir. The device also includes a pump having a pump housing containing a pump assembly and further having a receiving region to receive the cassette base region. The pump assembly includes a fluid drive component disposed proximate the receiving region, a main controller circuit board coupled to and configured to control the fluid drive component, and at least one secondary circuit board foldably joined to the main controller circuit board through a flexible substrate and disposed within the interior in a stacked relationship relative the main controller circuit board. | 2015-07-02 |
20150182699 | SYRINGE EXTENSION - Disclosed is an extension assembly for a syringe barrel. The assembly includes a housing having a side wall, a first end, a second end, and a coupling extending from the first end. The coupling is configured to attach to a syringe barrel. The assembly additionally includes a curved fluid channel extending from the coupling to a filling port. The filling port extends from the side wall and is configured to receive a vial which is selectively in fluid communication with the syringe barrel via the curved fluid channel. | 2015-07-02 |
20150182700 | PRESSURE-SENSING AUTOMATIC INJECTION SYSTEM - Disclosed is a system that senses the pressure of a suction cap and automatically performs injection. The present invention comprises: a suction motor for increasing the suction pressure to the suction cap of a suction injection needle; a solenoid valve having a solenoid valve controller connected thereto and having the function of relieving the suction pressure of the suction cap; a pressure sensor having a drug injection controller connected thereto and measuring the pressure of the suction cap; a drug injection motor operated by the drug injection controller on the basis of the pressure of the suction injection needle measured by the pressure sensor; a screw gear bolt connected to a syringe piston pusher which pushes a syringe piston along the lengthwise direction of a drug injection supporting portion; a screw gear shaft passing through the screw gear bolt and rotating according to the operation of the drug injection motor; and a connecting member for interconnecting the solenoid valve, the suction motor, the pressure sensor, and the suction injection needle. Thus, after the suction cap is attached to the skin, the pressure is sensed and a set amount of drugs is automatically injected. Therefore, the accuracy of drug treatment can be increased. | 2015-07-02 |
20150182701 | HIGH PRESSURE DELIVERY SYSTEM AND METHOD FOR TREATING PELVIC DISORDER USING LARGE MOLECULE THERAPEUTICS - The invention relates generally to methods and systems for the treatment of pelvic tissues using a high pressure injection device to deliver a therapeutic composition that includes a large molecule therapeutic agent, such as a nucleic acid or a polypeptide, to a target tissue in the pelvic area. Methods of the invention can improve delivery of the therapeutic agent into the tissue, which can be beneficial for the treatment of a pelvic tissue disorder, such as bladder and prostate tumors. | 2015-07-02 |